secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095439
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health Q2 revenue $2.4M; cuts FY cash guidance to $13-14.5M
--------------------------------------------------------------------------

- Q2 product revenue $2.4M vs $2.5M YoY; OvaSuite volume 6,471 units (+3%).
- Gross margin 59% vs 62% YoY; operating cash used $3.7M in Q2.
- Cash at June 30: $1.0M; subsequent raises of $4.0M boosted pro forma cash to $5.0M.
- Full-year 2024 cash guidance lowered to $13-14.5M from $15-18M.
- OvaWatch volume grew 48% YoY; John Kallassy appointed interim CFO effective Aug 15.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000095017024095439/0000950170-24-095439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000095017024095439/awh-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer